Comparative sector analysis positions the "KD stock forecast" above the industry average in terms of forward P/E ratios, indicating market confidence in earnings growth. According to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. In this instance, we’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. We find that Kyndryl Holdings’s ratio of 24.69x is trading slightly below its industry peers’ ratio of 29.24x, which means if you buy Kyndryl Holdings today, you’d be paying a decent price for it. And if you believe that Kyndryl Holdings should be trading at this level in the long run, then there’s not much of an upside to gain over and above other industry peers. Is there another opportunity to buy low in the future? Since Kyndryl Holdings’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Weekly performance metrics place the "KD stock forecast" in the top quartile of mid-cap tech stocks, outperforming peers by 4.3% over the last month.
